Actively Recruiting
Phase 1a1b Study of CT-95 for Treating Advanced Cancers with Mesothelin Expression
Led by Context Therapeutics Inc. · Updated on 2026-06-12
70
Participants Needed
9
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating CT-95, a drug designed to target advanced cancers that express mesothelin, including ovarian epithelial tumors, mesothelioma, lung adenocarcinoma, pancreatic adenocarcinoma, colorectal cancer, cholangiocarcinoma, and gastricGEJ adenocarcinomas. This Phase 1a1b, first-in-human, open-label study aims to assess the safety, how the drug moves and acts in the body, and its potential effects on tumors. The study involves multiple centers and includes dose escalation and expansion phases to find the best dosage. In Phase 1a, participants are assigned to one of about nine dose groups to determine the safety and maximum tolerated dose or recommended dose for expansion. CT-95 is given once weekly by intravenous infusion over a 4-week cycle. In Phase 1b, the recommended doses found in Phase 1a will be tested in 2 to 4 groups based on specific cancer types, with up to 80 participants total. Dose levels and schedules may be adjusted based on safety and early results from Phase 1a. Participants will receive CT-95 until disease progression, unacceptable side effects, or a decision to stop treatment. Researchers will monitor safety by tracking adverse events for about six months, measure drug levels in the blood, and assess tumor response every 8 weeks. Survival will be followed for up to two years after the first dose. Organ function and disease status will be evaluated to understand the drugs effects and tolerability throughout the study.
CONDITIONS
Brief Title
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Research Team
C
Context Clinical Development
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here